
Acute promyelocytic leukemia (APL) is a hematologic emergency in which all-trans retinoic acid (ATRA) should be initiated as soon as the disease is suspected; however, neoplastic and non-neoplastic conditions can closely mimic APL. This case-based narrative review examines findings that prompted suspicion of APL and those that led to diagnostic revision. A broadened literature search and patient-level extraction yielded 41 selected patients from 34 primary reports. Larger overlapping molecular cohorts and mechanistic studies were used for qualitative interpretation without adding their patients to the quantitative denominator. Median age was 48 years (range, 1.25–77), and 20 patients (48.8%) were female. Morphologic findings and an APL-like immunophenotype contributed to suspicion in 39/41 (95.1%) and 30/41 (73.2%), respectively; coagulation abnormalities contributed in 17/41 (41.5%). Negative PML::RARA or RARA-related testing contributed to diagnostic revision in 40/41 (97.6%), and identification of an alternative fusion or mutation contributed in 35/41 (85.4%). RARG rearrangements were identified in 14/41 patients (34.1%). All frequencies are descriptive and depend on reporting and variable-specific assessability. An APL-like phenotype is not equivalent to molecularly defined APL: rapid PML::RARA testing should accompany immediate empiric ATRA, and negative or equivocal results should prompt review of assay coverage and, when appropriate, orthogonal and broader molecular testing.
Background: Non-Hodgkin lymphoma (NHL) involving the ear, nose, and throat (ENT) region encompasses several established lymphoma entities with heterogeneous anatomical presentations. This study describes the clinicopathological features of a selected institutional cohort. Methods: We conducted a single-center retrospective case series of adult patients with NHL documented in institutional records during 2019–2021. Extranodal ENT-organ involvement was distinguished from cervical nodal disease without documented ENT-organ infiltration. Clinical, pathological, staging, treatment, and available follow-up information were reviewed descriptively. Results: Nineteen distinct patients were included (twelve in 2019, three in 2020, four in 2021). The median recorded age was 64 years, and 10 patients (52.6%) were male. Fourteen patients (73.7%) had extranodal ENT-organ involvement, and five (26.3%) had cervical nodal involvement only. The palatine tonsil was the most frequent index site (42.1%). Follicular lymphoma and mantle cell lymphoma were each recorded in four patients (21.1%). All final pathological diagnoses were recorded as B-cell lymphoma entities, although individual immunophenotypic findings were incomplete. Conclusions: This single-center retrospective case series highlights the anatomical and histopathological heterogeneity of NHL involving ENT-region structures. Larger multicenter studies with standardized clinicopathological assessment and longitudinal follow-up are needed to further characterize these presentations and their clinical outcomes.
Background/Objectives: Waldenström macroglobulinemia (WM) is a B-cell lymphoma, defined by immunoglobulin M monoclonal gammopathy, lymphoplasmacytic marrow infiltration, and impaired humoral immunity with increased infections. With advances in WM treatment, Bruton tyrosine kinase inhibitors (BTKis) are increasingly used as first-line therapy. Studies show that BTKi use in chronic lymphocytic leukemia is associated with partial humoral immune reconstitution and decreased rates of infections. This study investigates whether BTKi treatment for WM is associated with a reduced risk of infectious complications compared with traditional systemic therapies. Methods: In this single-institution retrospective analysis, we compared immunoglobulin levels and infectious complications in WM patients treated with BTKis, rituximab, or chemoimmunotherapy. Results: Treatment of WM with BTKis was associated with an increase in serum IgA levels by 33%. Rituximab monotherapy was also associated with increased IgA (9%), but after 24 months. Patients treated with BTKis developed fewer infections, 50% compared with 68.4–71.4% of patients in other groups. Severe infections (≥grade 3) occurred most frequently in patients treated with chemoimmunotherapy. There was no correlation between development of infections and serum IgG levels or neutrophil count. Conclusions: Results demonstrate that treatment with BTKis is associated with a decreased risk of infection over time due to partial humoral immune reconstitution, as evidenced by increasing serum IgA.
Background and Clinical Relevance: C5 inhibitors effectively control intravascular haemolysis (IVH) in paroxysmal nocturnal haemoglobinuria (PNH), but persistent extravascular haemolysis (EVH) may result in ongoing anaemia and transfusion dependence. Iptacopan, an oral complement factor B inhibitor, targets both mechanisms of haemolysis. Case Presentation: We report the 26-year clinical course of a female patient who developed PNH following severe aplastic anaemia. Despite long-term treatment with eculizumab and subsequently ravulizumab, she remained transfusion-dependent due to persistent EVH. The clinical course included three pregnancies, with successful delivery during the third following intensified eculizumab treatment and multidisciplinary management. Switching to iptacopan in 2024 resulted in normalization of haemoglobin, reticulocyte counts and lactate dehydrogenase levels, and complete transfusion independence. Conclusions: This case illustrates the evolving clinical and therapeutic challenges of aplastic anaemia-associated PNH over 26 years. It highlights the limitations of long-term C5 inhibition in controlling EVH and the potential of proximal complement inhibition to achieve sustained haematological recovery and transfusion independence.
Anemia is one of the most common health conditions worldwide, affecting people of different ages and backgrounds [...]